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Local Anesthetic Systemic Toxicity
Divya Garg, Shikha Soni and Rakesh Karnawat
Abstract
Local anesthetics are used very often in medicine and dentistry. They have few 
adverse effects, but the increased use of these drugs has resulted in a higher inci-
dence of local and systemic anesthetic toxicity (LAST). From the initial symptoms 
to the deleterious effects on cardiac and the central nervous system, LAST is an 
important consequence of which we should be aware. LAST is known since the 
introduction and use of local anesthetics; it was originally associated with seizures 
and respiratory failure. However, in the 1970s, side effects on the heart were also 
identified, as the fatal cardiac toxicity associated with bupivacaine was discovered 
in healthy patients. Prevention and safe administration of regional anesthesia 
remains primary factors in the avoidance of the toxicity of these drugs. When a 
patient has LAST, treatment should be started immediately to reduce seizures. If 
there is cardiac arrest, follow ACLS guidelines. Intravenous lipids improve cardiac 
conduction, contractility and coronary perfusion by removing liposoluble local 
anesthetic from cardiac tissue.
Keywords: local anesthetic, toxicity, mechanism of action, prevention, management, 
lipid emulsion
1. Introduction
Systemic toxicity due to local anesthetics (LAST) is a nightmare for each anes-
thesiologist. It can have catastrophic outcome in an otherwise simple procedure, 
such as a regional dental anesthesia, local anesthesia, nerve block either peripheral, 
intravenous or peridural. The clinical phenomenon of LAST has been known for 
more than 100 years. Historically, the introduction of cocaine as the first local 
anesthetic (LA) in late nineteenth century was soon accompanied by reports of its 
systemic toxicity. The symptoms of systemic toxicity were frequently described 
as seizures or respiratory failure, but some cases also included reports of adverse 
cardiac effects [1]. These reasons demanded medical and pharmaceutical industries 
to search for new less toxic LA.
At first, manipulation of existing molecular structures after analyzing natural 
products lead to development of few drugs. It became clear that the development 
of more LA of ester group did not return the desired results. The main concern was 
short duration of action due to instability of ester bonds. The drugs were prepared 
in an oily formulation to increase the duration (which proved neurotoxic locally, or 
by enhancing the lipophilicity of the molecule which made it more toxic to central 
nervous system (CNS) as well as cardiovascular system (CVS)). Lidocaine, synthe-
sized in 1944 was the first amide LA drug to be used clinically. It gave a dependable 
block, but unfortunately was short acting. In search of an LA with a longer duration 
of action than lidocaine, a family of N-alkylpiperidines 2,6 xylidides was introduced 
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in 1950s. It was shown that increasing N-alkyl carbon chain length (to max at C4 or 
C5) increased lipophilicity, which increases duration of action, but unfortunately 
also increased systemic toxicity. Derivatives developed for clinical use included 
mepivacaine, bupivacaine, ropivacaine, levobupivacaine, etc. But in subsequent 
year’s cases of lethal LAST were documented.
Accidental intravascular injection during regional anesthesia is the most com-
mon cause of LAST. Some comorbidities may increase the risk of LAST; liver failure, 
heart disease, pregnancy and metabolic syndromes. In addition, patients at extreme 
ages have an increased risk factor of toxicity, due to the reduction in anesthetic 
clearance. Children under 4 months of age have low plasma concentrations of acid 
glycoprotein, which may result in a lower intrinsic clearance of bupivacaine [2, 3].
The incidence of LAST is extremely variable from zero events after more than 
12,000 nerve blocks to 25 per 10,000 nerve blocks. One study reported seizures 
in 79 of 10,000 brachial plexus block procedures. This complication was due to 
toxicity of the CNS as a result of intravascular LA injection. Although the published 
data are inconsistent, the prevailing goal is to prevent LAST, and when it manifests, 
it must be treated quickly and effectively [4–6].
Cardiac toxicity is the most important component of LAST since, unlike the 
CNS toxicity, it can end in cardiac arrest and death. It is often due to an intravascu-
lar injection not noticed during nerve block. LA bind and inhibit voltage dependent 
sodium channels. It leads to conduction disorders, contractile dysfunction and ven-
tricular arrhythmias. The incidence of cardiac toxicity increases with bupivacaine 
due to its affinity for inactive sodium channels during the cardiac action potential at 
a concentration of 0.2 μg/mL. This is done in a fast/slow manner, which means that 
bupivacaine binds very rapidly to a large proportion of sodium channels during the 
potential for cardiac action, but is slowly released from the channels during dias-
tole, which results in a large proportion of medication that accumulates at 60–150 
beats per minute. Lidocaine at 5–10 μg/mL will also result in a substantial blockage 
of sodium channels during a potential for cardiac action. However, in contrast to 
bupivacaine, lidocaine follows the principle of rapid entry/exit, which means that it 
is rapidly released from sodium channels during diastole. This allows faster recov-
ery and a lower incidence of cardiac toxicity compared to bupivacaine.
CNS toxicity is another important consequence of LAST. Although it is com-
posed of many initial prodromal features, it is most often manifested as seizures. 
A mechanistic theory focuses on acid-sensitive K+ channels. These pH-sensitive 
channels generate neuronal currents of leakage of potassium. LA inhibition causes 
membrane depolarization and increased neuronal excitability. As these channels 
are expressed throughout the brain, this is the suggested mechanism for seizures in 
this context. Consequently, it became mandatory to understand the mechanism of 
LAST, so that it could be prevented and managed efficiently.
This chapter reviews the mechanisms, frequency, clinical characteristics, 
prevention and treatment of LAST.
2. LAST mechanisms
LA agents are classic sodium channel inhibitors. LAST hypotheses are based 
primarily on the binding site, ion channels, signaling pathway or enzymes involved 
in the CNS and cardiac toxicity or its treatment. LA inhibit some components of 
the oxidative phosphorylation pathway, which affects the myocardium and the CNS 
that are poorly tolerant of anaerobic metabolism. These deleterious effects differ 
quantitatively between LA, doses and administration routes. It is appropriate to first 
review the ion channels implicated in LAST [7–9].
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2.1 Sodium channel blockade
LA are sodium channel blocking acting on inactivated sodium channel state and 
blocking it. They affect the initial depolarization phase and slow it down, leading to 
slow cardiac conduction. The antiarrhythmic property of lidocaine is related to this 
slowed conduction as it causes fast blockade of the channels. In contrast, bupiva-
caine and ropivacaine cannot be used as anti-arrhythmic drugs though they have 
fast blockade, but slow release of sodium channel (lasting longer than 1 s in contrast 
to lidocaine which lasts 0.15 s) [10]. Slowed conduction leads to widening the QRS 
complex, prolongation of the PR interval, AV block and, eventually, ventricular 
fibrillation due to the unidirectional blockade and re-entry phenomenon.
2.2 Potassium channel blockade
Out of three known organized potassium channels, two groups are of interest 
where LA toxicity is concerned. Out of these, one group of channels are known 
as the inward, outward and transient rectifier potassium channels, thus plays an 
important role in the potassium efflux during phases 2 and 3 of the cardiac muscle 
action potential [11]. If these channels are blocked, it will lead to prolongation 
of action potential; i.e. phase 2, delay in repolarization; i.e. phase and shift the 
resting membrane potential more positive (phase 4) to increase automaticity [12]. 
The second group of potassium channels of interest are K2p. Previously known 
as the delayed rectifier channels, these channels are believed to be responsible for 
the background or leak potassium currents. In this setting, they control the resting 
membrane potential. A blockade of these channels shifts the resting membrane 
potential towards spontaneous depolarization. K2p channels are extensively 
spread in the body. In the CNS they are mainly located in the thalamo-cortical and 
striatal neurons, where blockade leads to increased neuroexitability [13]. They are 
also present in high concentrations in the cerebral blood vessels, where blockade 
leads to vasoconstriction and decreased cerebral blood flow. K2p channels are also 
present in neurons of the auditory system, where blockade leads to tinnitus. LA 
agents are also known to have K2p mediated stimulating effect on ventilation [14]. 
They are located in the brainstem and carotid body, where they regulate the respi-
ratory response to carbon dioxide via sensing the changes of pH and expressed 
in the oxygen-sensing cells of the glomus body respectively. K2p channels are 
sensitive to changes in oxygen tension and extracellular pH and are potentiated by 
volatile anesthetic [13]. In the CVS K2p channel blockade predisposes the patient 
to re-entry dysrhythmias. It is well known that hyperkalemia exacerbates LAST, 
and that K+ATP openers (which effectively lowers intracellular K+ levels) attenuate 
the toxic effects of bupivacaine [15].
2.3 Ca2+ channel blockade
All voltage-gated Ca2+ channels are comprised of two subunits according to 
the latest research: α and β subunit. The α subunit has fairly constant chemical 
structure for all voltage gated Ca2+ channels and is the main pore- forming ele-
ment of the channel. The β subunit has highly variable structure that depends on 
the location and function of the channel for e.g. in cardiac conduction tissue β1 
subunit completes the ion channel structure. The role of the β1 subunit seems to be 
the modulation of channel opening and membrane ion trafficking [16]. In terms 
of their physiological effect, the heart has two distinct types of channels namely 
the T-type (transient) that are low voltage activated channels (LVA), and L-type 
(long lasting). On the other hand, are high voltage activated channels (HVA). 
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The T-type channels are mainly located in the pacemaker cells of the sinoatrial node, 
and the opening of these channels completes the prepotential required for the 
pacemaker potential. L-type channels are present on the surface of the myocytes of 
both atrium and ventricle, and are closely associated with the T-tubules. The plateau 
phase (phase 2) of cardiac muscle action potential is produced by opening of these 
L-type channels. LA bind to these channels and predispose them to an inactivated 
state. The consequence of this is prolongation of the action potential (phase 2) and 
depressed contractility [9].
3. LAST risk factors
Risk factors to develop LA toxicity are related to kind of LA used, the type of 
nerve block, and the patient.
3.1 LA related
The most important and most studied factors in the development of LAST are 
undoubtedly the type and dose of LA.
3.1.1 Type of LA
The kind of LA injection influence toxicity risk. Animal studies showed that [17] 
more levobupivacaine than bupivacaine was required to induce cardiac arrest and 
levobupivacaine caused fewer convulsions and arrhythmias than bupivacaine, at 
similar doses [18]. Ropivacaine may cause less motor block, but whether it is clini-
cally significantly less toxic is unknown. Other property differentiating the toxicity 
of LA is their intrinsic effect on vessels, where levobupivacaine and ropivacaine 
have intrinsic vasoconstrictors properties (that may prolong duration of action and 
slow systemic absorption), whereas bupivacaine is an intrinsic vasodilator. The 
clinical significance of this difference remains unclear. Another important concept 
in the study of LAST is the ratio of the dose required to produce cardiovascular 
collapse to that required to induce seizures, the so called CC/CNS ratio (ratio of 
dose causing cardiovascular collapse to the dose causing seizures). Bupivacaine has 
a CC/CNS ratio of 2.0 compared with 7.1 for lidocaine. Therefore, progression from 
CNS signs and symptoms to cardiovascular collapse can occur more readily with 
bupivacaine than with lidocaine.
3.1.2 Dose of LA
Determining the optimal dose of LA to use is complex and always a topic of 
debate. Using the lowest effective dose is always prudent and advisable practice 
along with consideration of patient characteristics and site of administration. 
Some may argue that the recommended doses provide a rough guide for clini-
cal use. The maximum weight-based doses have lost rationale in others view as 
such dosing does not correlate to the resulting blood level and does not take into 
account relevant patient factors or the site of injection. Other factors that ques-
tion the maximum weight based doses are variation between different texts and 
countries, no recommendation whether dose calculation is based on actual body 
weight or ideal body weight and such hard and fast dosing rules do not take into 
account the complete clinical context [19]. As a result, if dosing is calculated on 
actual body weight, the obese, pregnant, or both patients may receive a danger-
ously high dose.
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3.2 Block-related
Inadvertent intravenous injection of LA can occur during any regional anes-
thetic technique, but tends in becoming LAST only if larger volumes (5–10 mL) 
are injected, or small doses during face and neck procedures. Symptoms usually 
occur within 3–5 min and can be severe if appropriate measures are not taken. 
LAST resulting from the gradual systemic absorption of LA is characterized 
by a late presentation (20–30 min or more after a bolus injection), and usually 
occurs when a relatively high dose of LA has been administered in the presence 
of another risk factor. Local anesthetic systemic toxicity may also occur in the 
context of continuous LA infusion, in which case the onset may be hours to days 
after starting the infusion. The symptoms last until the drug metabolism reduces 
concentrations plasma levels below the toxic threshold. Prolonged monitoring and 
supportive therapy are essential.
3.2.1 Site of block
Blocking site is important since rate of absorption, chances of direct intravascu-
lar injections and thus chances of toxicity depends on the anatomical location. For 
example, interscalene block, stellate ganglion block, intercostal nerve block have a 
higher risk of direct intravascular injection and other blocks like scalp, bronchial 
mucosa, inter pleural cavity carry an increased risk of rapid absorption and toxicity 
due to the injection being in a highly vascularized area. The classic order of sites 
propensities to lead to toxicity, in order from lowest to highest: subcutaneous injec-
tion, brachial plexus, epidural, caudal, and finally intercostal blocks and topical 
mucosal anesthesia.
3.2.2 Conduct of the block
Performing the block in a safer way decreases the chances of toxicity by mani-
folds. The practice of giving the dose of LA in incremental injections, after frequent 
aspiration, adding test dose and most important is using ultrasound-guided needle 
placement to give the LA reduces the risk of toxicity.
3.3 Patient-related factors
3.3.1 General principles
Various factors are related to toxicity of LA. Most common being the free peak 
plasma concentration, perfusion at the site of injection, co-morbidities (renal, liver, 
metabolic, and cardiac diseases). As already discussed earlier, more the perfusion 
at the site of injection, more will be the peak plasma concentration as systemic 
absorption is accelerated. A low α1-acid glycoprotein (AAG) titer results in a higher 
concentration of free LA.
In patients with severe renal impairment there may be slightly increased risk of 
toxicity as these patients typically have a reduced clearance of LA, hyper dynamic 
circulation but increased AAG. So, it is prudent to reduce the initial dose by 10–20% 
according to severity of renal impairment.
In patients with liver disease, single dose blocks are unaffected, but the doses for 
repeat boluses and continuous infusions should be reduced. Such patients may also 
have renal or cardiac disease. AAG is synthesized in patients with end-stage liver 
disease, offering some protection against LAST. Patients with severe cardiac failure 
are particularly susceptible to LA-induced myocardial depression and arrhythmias. 
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Further, lower liver and renal perfusion slows metabolism and elimination, so safe 
initial and maintenance doses of LA are correspondingly lower too. On the other 
hand, poor perfusion at the injection site may decrease peak plasma concentrations.
3.3.2 Age related factors
Extremes of age have different physiological changes making them different 
from young and adolescent age group. In elderly patients; there is a safety benefit in 
dose reduction without altering the clinical efficacy. In the geriatric patient’s nerves 
appears to be more sensitive to LA due to various factors like altered nerve mor-
phology, there is less fat tissue surrounding the nerves, and axonal function is also 
reduced. Moreover, this age group has multiple co-morbidities and decreased muscle 
mass; blood flow to organs is reduced, decreased clearance and organ function. In 
patients older than 65 years’ involuntary overdoses being responsible for some cases 
of LAST. When considering the use of LA in geriatric patients, it is mandatory to pay 
special attention to the presence of systemic disease and muscle wasting [20].
In neonates and infants, the risk of accumulation of LA with continuous infu-
sions is more than in adults as AAG levels are reduced (about half that of adult at 
birth). Children have an increased elimination half-life of LA, which in neonates is 
increased to 2–3 times that of an adult. Bupivacaine accumulates with continuous 
infusion and 2-chloroprocaine can be used as an alternative. LAST has the highest 
incidence in infants less than 6 months of age and is associated with bolus dosing 
and penile nerve blocks [21].
3.3.3 Pregnant patients
Pregnancy is one of several clinical settings in which LAST can be potentiated. 
Pregnant patients are at an increased risk of toxicity as they have increased perfu-
sion as well as decreased AAG levels; thus high peak free plasma concentration of 
LA. Some of the earliest anecdotal reports of LAST-related fatal cardiac arrests 
involved pregnant women [1]. Notably, several of the original anecdotal reports 
of LAST-related fatal cardiac arrests involved pregnant women. It has since been 
proven that pregnancy increases the risk for LAST, and subsequent guidelines 
preclude use of 0.75% bupivacaine in late gestation because this concentration was 
involved in cases of fatal toxicity in parturients [22–24].
4. Clinical presentation of LAST
Most of the LAST events happen a few minutes after the LA injection and pres-
ent with signs of the CNS, which may or may not be accompanied by changes in the 
CVS (Figure 1). Sometimes, the manifestations are atypical in terms of time and 
clinical picture. The onset of symptoms may be delayed up to 60 min after a bolus 
injection, and signs of CVS toxicity may appear in the absence of any CNS charac-
teristics. This last scenario may be more common in patients who are very sedated 
or under general anesthesia. High plasma concentrations during LAST can occur 
in three circumstances: inadvertent intra-arterial injection, intravenous injection 
or systemic absorption, each of which has a characteristic temporal course. LAST 
associated with intra-arterial injection occurs classically during nerve blockages in 
the head and neck (stellate ganglion, interscalene or deep cervical plexus blocks) 
in which there is an involuntary injection of LA in an artery that supplies the brain. 
The symptoms of the CNS, usually seizures, occur almost immediately. When 
the injected dose is small, progression to CVS collapse is uncommon. Recovery 
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is equally rapid since LA quickly redistributes from the cerebral circulation [25]. 
Figure 2 shows an intra-arterial puncture detected during the blockage of the stel-
late ganglion in a patient with herpes zoster neuropathy.
4.1 Central nervous system toxicity
Central nervous system toxicity could be presumed as a two-stage process in 
which initial blockade of Na+ channels occurs in the inhibitory neurons thus allow-
ing excitatory neurons to act unopposed which culminates in generalized convul-
sions. Higher concentrations of LA agent affect all neurons, leading to global CNS 
depression, which is clinically seen as coma and evident on EEG as slowing and 
ultimately silent EEG. In most cases, convulsions, although an impressive clinical 
entity, can be handled safely without permanent brain damage. Clinical manifesta-
tions of the systemic neurotoxicity of LA usually occur in stages; in the initial phase 
there is perioral numbness, confusion, tinnitus followed by an exciting phase that 
shows seizures and, finally, a depressive phase where there is loss of consciousness 
and respiratory depression.
Figure 1. 
Scheme showing the most important clinical manifestations of LAST.
Figure 2. 
Accidental arterial puncture during a stellate ganglion block in a patient with postherpetic neuropathy.
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4.2 Cardiovascular system toxicity
Both the direct and indirect effects of the LA drugs on myocardium are involved 
in the mechanism of cardiovascular toxicity [26].
Clinical presentation includes hypertension and tachycardia in initial phase 
(during CNS excitatory phase), followed by intermediate phase showing myocar-
dial depression, decreased cardiac output and thus hypotension, followed by sinus 
bradycardia, peripheral vasodilatation, conduction defects and dysrhythmias in 
terminal phase.
5. Management of LAST
All medical and paramedical personnel working in operating theaters and hospi-
tal locations where LA are used should be prepared to recognize, diagnose and treat 
patients with signs and symptoms of LAST in a timely manner. The ASRA has pub-
lished and updated the guidelines recommended by experts for the management of 
LAST (Table 1) [4, 5]. The initial treatment of LAST should focus on keeping the 
airways permeable with adequate ventilation, circulatory support and the reduction 
of systemic side effects. Immediate ventilation and oxygenation to prevent hypoxia 
and acidosis can facilitate resuscitation and reduce the likelihood of progression to 
seizures or cardiovascular collapse [24, 25].
5.1 Preparation
All patients receiving LA injections in doses potentially to trigger LAST should 
have oxygen, standard monitoring which is to be continued at least 30 min after 
completion of injection to detect delayed presentation if any, and intravenous access 
applied [27, 28]. Immediate access to LAST Management Checklist is advisable, and 
all medications and resuscitation equipment required should be immediately avail-
able, preferably in the form of a “LAST Rescue Kit”.
5.2 Immediate management
Immediate management involves the general safety and resuscitation measures 
that are essential in any emergency. First, stop LA injection and call for help. The 
immediate priority is to manage the airway, breathing, and circulation. Avoid 
factors potentiating LAST like hypoxia, hypercarbia, and acidosis (metabolic or 
respiratory [24, 25, 29]).
5.2.1 Intravenous lipid emulsion therapy
Use of intravenous lipid emulsion as a therapeutic modality comes with several 
advantages. Theories suggest that it improves cardiac conduction, contractility 
and coronary perfusion by removing the liposoluble LA from cardiac tissue. Better 
understanding of the mechanism of action of lipid emulsion with recent advances 
underlines its importance as therapeutic modality in the management of LAST. First 
advantage is that lipid emulsion may shuttle any LA agent from high blood flow 
organs to detoxification organs such as the liver [30]. Secondly, lipid emulsion 
therapy may also improve the cardiac output and blood pressure. Post conditioning 
myocardial protection may also occur [31–34]. There is an unavailability of large 
scale data collection and other prospective studies to demonstrate efficacy of lipid 
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emulsion therapy due to various difficulties [24, 35, 36]; however various animal 
studies provide strong support for use of lipid emulsion therapy to reduce mortality 
when used along with resuscitative measures [37]. Early administration of 20% 
intravenous lipid emulsion therapy should, therefore, be an immediate priority 
after airway management in any LAST event that is judged to be potentially seri-
ous. A bolus of 1.5 mL/kg of 20% lipid emulsion and the subsequent infusion of 
0.25 mL/kg per minute should be administered. The infusion should be continued 
for 10 min after reaching hemodynamic stability. An additional bolus and an infu-
sion rate increase to 0.5 mL/kg per minute can be administered if stability is not 
achieved. The maximum recommended dose for initial administration is approxi-
mately 10 mL/kg for 30 min (Table 1) [4, 37, 38]. Lipid emulsion remains first-line 
therapy (in conjunction with standard resuscitative measures) in LAST. However, 
more research in humans is necessary to establish its real usefulness [36].
Checklist for LAST treatment
The pharmacologic treatment of LAST is different from other cardiac arrest scenarios
 Reduce individual epinephrine boluses to ≤1 mcg/kg
 Avoid vasopressin, calcium channel blockers, beta blockers, or other local anesthetics
• Stop injecting local anesthetic
• Get help
 ○ Consider lipid emulsion therapy at the first sign of a serious LAST event
 ○ Call for the LAST rescue kit
 ○ Alert the nearest cardiopulmonary bypass team – resuscitation may be prolonged
• Airway management
 ○ Ventilate with 100% oxygen / avoid hyperventilation / advanced airway device if necessary
• Control seizures
 ○ Benzodiazepines preferred
 ○ Avoid large doses of propofol, especially in hemodynamically unstable patients
• Treat hypotension and bradycardia—if pulseless, start CPR
Lipid emulsion 20% (precise volume and flow rate are crucial)
Greater than 70 kg patient Less than 70 kg patient
Bolus 100 mL lipid emulsion 20% rapidly over 2–3 min Bolus 1.5 mL/kg lipid emulsion 20% 
rapidly over 2–3 min
• Lipid emulsion infusion 200–250 mL over 15–20 min • Lipid emulsion infusion ~0.25 mL/kg/
min (ideal body weight)
If patient remains unstable:
• Re-bolus once or twice at the same dose and double infusion rate; be aware of dosing limit (12 mL/kg)
• Total volume of lipid emulsion can approach 1 L in a prolonged resuscitation (e.g., > 30 min)
• Continue monitoring
 ○ At least 4–6 h after a cardiovascular event
 ○ Or, at least 2 h after a limited CNS event
• Do not exceed 12 mL/kg lipid emulsion (particularly important in the small adult or child)
 ○ Much smaller doses are typically needed for LAST treatment
With permission from www.anestesia-dolor.org.
Table 1. 
Checklist for LAST treatment [4, 5].
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5.2.2 Seizure management
Prompt seizure prevention and termination is crucial to avoid injury and acido-
sis. Benzodiazepines are first line therapy for management of seizures due to their 
cardio stable profile. Propofol or thiopental can be used in low doses, although these 
drugs may worsen the hypotension or cardiac depression associated with LAST. It 
should be avoided in patients with cardiovascular compromise. Neuromuscular 
blockade can be considered in cases of ongoing seizures; small doses of succinyl-
choline should be administered intermittently to stop muscle activity and increased 
acidosis. Early termination of seizure activity helps to avoid metabolic acidosis and 
hypoxia that occurs due to repeated muscular contractions [24].
5.2.3 Cardiovascular support
The treatment of LA-induced cardiac arrest focuses on restoring cardiac 
output, to restore tissue perfusion, prevent and treat underlying acidosis. Chest 
compressions should be started without delay and to be continued till return of 
spontaneous circulation (as per ACLS algorithms for cardiopulmonary resuscita-
tion). If epinephrine is used, small initial doses of ≤1 μg/kg are preferred to avoid 
impaired pulmonary gas exchange and increased afterload [39]. Vasopressin is not 
recommended, as it can cause pulmonary hemorrhage. If myocardial LA levels is 
more than the threshold that corresponds to ion channel blocking concentrations, 
then the ionotropic effect of lipid emulsion therapy remains questionable. Chest 
compressions ensure the coronary perfusion that is sufficient to reduce tissue LA 
levels. In the absence of rapid recovery following ACLS measures and intravenous 
lipid emulsion therapy, early consideration should be given to cardiopulmonary 
bypass for circulatory support. For other deleterious CVS effects—such as arrhyth-
mias, conduction block, progressive hypotension, and bradycardia – standard 
ACLS algorithms should be followed with the omission of LA, such as lidocaine and 
procainamide. Amiodarone is the first-line antiarrhythmic in the event of ventricu-
lar dysrhythmia. In addition, calcium channel blockers and B-adrenergic receptor 
blockers are not recommended.
5.2.4 Post-event management
Report the case of LAST to the registry at www.lipidrescue.org [39]. Monitoring 
is mandatory for at least 2 h in isolated and recovering CNS event but for 6 h for 
LAST with CVS features.
6. Prevention
The primary objective of every anesthesiologist is always patient safety. Pre-
anesthetic evaluation, patient preparation, complete monitoring before starting 
administration of LA, and continuing this monitoring during surgery and the 
immediate postoperative period are mandatory.
6.1 Pre-procedure
• During preoperative assessment, evaluate the patient for co-morbidities, 
evaluation of the risks and benefits of regional anesthesia for that individual 
should be discussed, patient should be explained regarding procedure and 
appropriate consent to be obtained.
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• Preparation includes selection of type of LA, prior calculation of doses, label-
ing all syringes.
• All monitoring facilities to be available along with LAST rescue kit and resusci-
tative measures.
6.2 Intra-procedure
• Block to be performed with continuous monitoring attached, with a capable 
help nearby.
• The method of administration of LA should include the administration of 
incremental doses with frequent aspiration, ultrasound-guided needle place-
ment, administration of test doses. This can help in the early detection of 
accidental intravascular placement of the needle or catheter and thus avoid 
erroneous administration of the LA, avoiding toxic plasma concentrations.
• Continuous communication with the patient to detect early signs of intravas-
cular injection like perioral numbness, tinnitus etc.
6.3 Post-procedure
Clearly label any kind of spinal/epidural catheter or peripheral nerve block 
catheter; it should be documented well in patient chart also. Drug and dose already 
administered or to be administered should be well informed in instructions to the 
medical staff responsible for post-operative care of the patient. Continuous moni-
toring of vital signs in the postoperative period in suspected case of delayed LAST 
to be considered.
7. Conclusion
LAST is a serious life-threatening emergency, with protean manifestations, that 
can happen after administering LA. Anesthesiologists must understand its risks, 
prevention, and safe management. Promptly recognition and timely manage-
ment of LAST can dramatically change the clinical course. In addition to the usual 
advanced cardiac resuscitation maneuvers, the current treatment focuses on the 
administration of lipid emulsion. While the development of new treatment plans 
can help limiting the associated morbidity and mortality, prevention remains 
vitally important. It is mandatory for all the practitioners using LA to understand 
patho-physiological basis, mechanisms, risk factors, prevention and treatment 
modalities of LAST.
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